Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing

Type I interferon (IFN) has been approved as an anticancer agent to treat some malignancies. However, IFNs have a short in vivo half-life, systemic toxicity, and poor biophysical properties, which prevent it from being widely used for cancer therapy. This study aimed to construct recombinant IFN-β-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chan Gyu, Kim, TaeEun, Hong, Sungyoul, Chu, Jongwan, Kang, Ju Eun, Park, Hee Geon, Choi, Jun Young, Song, Kyoung, Rha, Sun Young, Lee, Soohyeon, Choi, Joon-Seok, Kim, Sun Min, Jeong, Hae Min, Shin, Young Kee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832035/
https://www.ncbi.nlm.nih.gov/pubmed/33505314
http://dx.doi.org/10.3389/fphar.2020.608774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832035/
https://www.ncbi.nlm.nih.gov/pubmed/33505314
http://dx.doi.org/10.3389/fphar.2020.608774

Ejemplares similares